Algernon Pharmaceuticals Inc. C.AGN

Enrollments for Phase 2B Study

[Arbourmark]

In the news release today the company stated the following:

Phase 2b Study Completion and Data Readout 

The Company will provide an update to the market on a projected completion date of the study as well as when the read out of the data can be expected when enrollment in the study reaches the 50% target level.

The phase 2B study accounts for 150 patients and today they announced patient count at 50. I believe based on comments above they will be providing a update once they have 75 patients enrolled which should happen pretty quickly in my opinion.

They also stated they expected to see enrollments pick up each week which suggests they may enroll the 150 faster than what they initially thought.

[talisman47]

I agree. I would assume if an enrolled patient is being treated and that hospital is seeing positive results happening that they would want to enrol more patients in the program as quickly as possible. Results may not be out to the public , however, hospital doctors would be seeing early on if the drug seems to be working.  Stay positive...

[Raddnar]

Fortunately, studies aren’t done that way or doctors would be able to take advantage of insider trading. The doctors and nurses administrating agnpf’s ifenprodil study for both covid and chronic cough don’t know which patients are receiving ifenprodil. The trial is 3 part, 1 is a higher dose, 1 is a lower dose, and 1 is nothing.  Once the trials are compelte, the patient data is sent to